D. Boral Capital Reiterates Buy Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other research firms have also recently issued reports on CANF. StockNews.com started coverage on shares of Can-Fite BioPharma in a research report on Thursday, February 27th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Stock Down 6.1 %

Shares of NYSE:CANF opened at $1.62 on Monday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The stock has a market cap of $5.72 million, a P/E ratio of -0.90 and a beta of 1.33. The business has a fifty day moving average of $1.58 and a two-hundred day moving average of $1.93.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets bought a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent reporting period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.